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OBJECTIVES The present study was designed to evaluate the relationship between the presence of aortic
sclerosis, serologic markers of inflammation, and adverse cardiovascular outcomes.
BACKGROUND Aortic sclerosis is associated with adverse cardiovascular outcomes. However, the mechanism
by which such nonobstructive valve lesions impart excess cardiovascular risk has not been
delineated.
METHODS In 425 patients (mean age 68  15 years, 54% men) presenting to the emergency room with
chest pain, we studied the relationship among aortic sclerosis, the presence and acuity of
coronary artery disease, serologic markers of inflammation, and cardiovascular outcomes.
Patients underwent echocardiography and serologic testing including C-reactive protein
(CRP). Aortic valves were graded for the degree of sclerosis, and cardiovascular outcomes
including cardiac death and nonfatal myocardial infarction (MI) were analyzed over one year.
RESULTS Aortic sclerosis was identified in 203 patients (49%) , whereas 212 (51%) had normal aortic
valves. On univariate analysis at one year, patients with aortic sclerosis had a higher incidence
of cardiovascular events (16.8% vs. 7.1%, p  0.002) and worse event-free survival (normal
valves  93%, mild aortic sclerosis  85%, and moderate to severe aortic sclerosis  77%, p
 0.002). However, by multivariable analysis aortic sclerosis was not independently associated
with adverse cardiovascular outcomes; the only independent predictors of cardiac death or MI
at one year were coronary artery disease (hazard ratio [HR] 3.23, p  0.003), MI at index
admission (HR 2.77, p  0.008), ascending tertiles of CRP (HR 2.2, p  0.001), congestive
heart failure (HR 2.15, p  0.02) and age (HR 1.03, p  0.04).
CONCLUSIONS The increased incidence of adverse cardiovascular events in patients with aortic sclerosis is
associated with coronary artery disease and inflammation, not a result of the effects of valvular
heart disease per se. (J Am Coll Cardiol 2004;43:169–75) © 2004 by the American College
of Cardiology Foundation
Aortic sclerosis was until recently considered a benign
degenerative process of the elderly. However, recent obser-
vations demonstrate that aortic sclerosis is associated with
an increased incidence of myocardial infarction (MI) and
cardiovascular death (1–3). Because aortic sclerosis does not
itself cause sufficient hemodynamic perturbations to impact
cardiovascular function, the mechanisms underlying its as-
sociation with adverse cardiovascular outcomes are unclear.
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Histopathologic studies have shown striking similarities
between degenerative aortic valve disease and coronary
atherosclerosis (4–6), with evidence of inflammation com-
mon to both conditions. Inflammation is an important
mechanism underlying the pathophysiology of chronic ath-
erosclerosis (7–10) and has also been implicated in the
precipitation of coronary plaque rupture (8,11–15). Obser-
vations in patients with acute coronary syndromes suggest
that plaque inflammation is a multifocal coronary process
associated with elevated systemic markers of inflammation
(16,17).
Whether systemic activation of inflammatory processes
secondarily exerts extrinsic adverse influences on coronary
atherosclerosis and plaque stability, or whether these sero-
logic findings are merely systemic markers of primary
coronary inflammation triggered by intrinsic arterial mech-
anisms, has not been fully elucidated. Regardless of the
nature of the link, the association between elevation of
serologic markers of inflammation and increased cardiovas-
cular events in patients with both chronic coronary artery
disease (CAD) and in those with acute coronary syndromes
is well documented (18–22). Recent evidence suggests that
chronic inflammation may play a role in the pathogenesis of
aortic sclerosis as well (4–6). On the basis of these obser-
vations, we hypothesized that the association between aortic
sclerosis and adverse cardiovascular events is unlikely to be a
direct pathophysiologic link, but may be attributable to
active CAD with an inflammatory link.
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METHODS
We studied the relationship among aortic sclerosis, the
presence and acuity of CAD, serologic markers of inflam-
mation, and cardiovascular outcomes in patients presenting
with chest pain to the emergency room by prospective
follow-up of a cohort of patients from an observational
cross-sectional study, Chlamydia Pneumoniae Exposure
and Inflammatory Markers in Acute Coronary Syndrome
(CIMACS); the detailed methodology of the study has been
published earlier (23). In brief, patients were enrolled at
William Beaumont Hospital from March to June 1999.
Patients had a 12-lead electrocardiogram (ECG) and car-
diac enzymes evaluation. A subset of patients underwent
two-dimensional echocardiographic evaluation at the dis-
cretion of the attending physician. Patients were excluded
for aortic stenosis (peak velocity 2 m/s, prosthetic aortic
valves, age 18 years, any malignancy requiring treatment
within the previous two months, acquired immunodefi-
ciency syndrome, chronic steroid use, immunosuppressive
therapy (such as for transplantation), chronic liver disease,
inflammatory bowel disease, rheumatoid arthritis, systemic
lupus erethematosis, and any major surgery within the past
two months. Patients with multiple visits during the period
were enrolled only at their first visit.
Echocardiography. Two-dimensional Doppler echocar-
diograms (HP5500 or HP5000, Agilent Technologies,
Andover, Massachusetts) were blindly reviewed by three
experienced observers. The aortic valve was analyzed using
parasternal long- and short-axis views. Aortic sclerosis was
defined as increased echogenicity, thickening, or calcifica-
tion of the leaflets. Although no prior study has graded
aortic sclerosis, we noted significant variations in echoge-
nicity, thickening, or calcification of the valve leaflets on
echocardiography and found it reasonable to employ these
features to construct a qualitative grading system. The
severity of aortic sclerosis was graded on a scale of 0 to 3: 0
 normal (no involvement), 1  mild (minor involvement
of one leaflet), 2  moderate (minor involvement of two
leaflets or extensive involvement of one leaflet), and 3 
severe (extensive involvement of two leaflets or involvement
of all three leaflets). Discrepancies in scoring were resolved
by consensus among the observers. Peak Doppler velocity
across the valve was measured.
Serologic testing. Complete blood count, blood urea ni-
trogen, and creatinine were obtained. Creatinine kinase
(CK), CK-MB, and troponin-T were measured using elec-
trochemiluminescence immunoassay (Roche Elecsys 1010/
2010, Tokyo, Japan). High sensitivity C-reactive protein
(CRP) levels were determined employing a commercial
assay (Dade Behring BN II system, Newark, Delaware).
Fibrinogen was measured using the MDA 180 method
(Organon Teknika MDA 180 coagulometer, Oklahoma
City, Oklahoma). In order to test whether prior infection
with Chlamydia pneumoniae was associated with the condi-
tions studied, immunoglobulin G (IgG) antibodies against
C. pneumoniae were measured using microimmunofluores-
cent assay (ARUP Laboratory, Salt Lake City, Utah).
Clinical outcomes. Clinical outcomes were analyzed by
chart review. Acute coronary syndromes included MI and
unstable angina. Myocardial infarction was defined as chest
discomfort with abnormal cardiac enzymes (twofold in-
crease in total creatine kinase enzyme with creatine
kinase-MB fraction 3.9%). Unstable angina was defined
as chest discomfort with or without ECG changes, together
with either noninvasive stress imaging (sestamibi or two-
dimensional echocardiographic) documentation of ischemia
or angiographic evidence of significant (70%) coronary
artery stenoses. Charts were reviewed to analyze clinical
variables. To analyze one-year cardiovascular outcomes (MI
or death from cardiovascular causes), patients (or family
members) were contacted by telephone and findings were
confirmed by review of medical records.
Statistical analysis. Moderate and severe aortic sclerosis
groups were combined for the analysis. Recognizing the
limitations of echocardiographic qualitative grading, we
compared normal valves with any aortic sclerosis and with
groups with increasing severity of aortic sclerosis. All
normally distributed continuous variables were compared
using Student t test . Categorical variables were compared
using chi-square test (or Fisher exact test where appropri-
ate). Alpha of 0.05 was used to define statistical significance.
All inflammatory markers (CRP, fibrinogen, and leuko-
cyte counts) were non-normally distributed and hence were
compared as continuous variables after log normalization
and computation of geometric means. Median values of
these variables were computed and compared using
Wilcoxon’s rank-sum test. Tertiles of the inflammatory
markers were also computed and used for relative ratio
analysis for adverse outcome at one year. IgG antibody titers
against C. pneumoniae were compared both as a continuous
variable (using reciprocal of the titer) and as a dichotomous
variable at different levels:  or 1:64,  or 1:128,  or
1:256,  or 1:512, and  or 1:1,024 (instead of using
an arbitrary definition of seropositivity).
Multivariable logistic regression was done using presence
or absence of aortic sclerosis as the dependent variable, and
clinical, laboratory, and inpatient outcome variables found
to have an association on univariate analysis at alpha 0.10.
Using logistic regression analysis (where the dependent
variable was adverse cardiovascular outcome at one year),
the unadjusted relative risks with 95% confidence interval
were computed for variables of clinical interest. Kaplan-
Meier survival analyses were performed to evaluate the
Abbreviations and Acronyms
CAD  coronary artery disease
CRP  C-reactive protein
ECG  electrocardiogram
IgG  immunoglobulin G
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one-year outcome according to the severity of aortic sclero-
sis, and tertiles of CRP in patients with aortic sclerosis. The
Cochran-Mantel-Haenszel statistic was used for analysis of
trend. Cox proportional hazard model was used for multi-
variable regression analysis using variables found to have
univariate association with adverse cardiovascular outcome
at one year at alpha 0.10. Statistical analysis was per-
formed using SAS version 6.12.
The study was approved by the institutional Human
Investigation Committee. All patients provided informed
consent.
RESULTS
We screened 830 patients with chest pain to identify 425
who underwent echocardiography. Five patients were sub-
sequently excluded because of inadequate echocardiographic
views of the aortic valve and three were excluded because of
aortic stenosis, as were two others with prosthetic aortic
valves. The remaining 415 patients constitute the popula-
tion analyzed in this study, of whom 212 (51%) patients had
normal aortic valves, 149 (36%) had mild aortic sclerosis, 47
(11%) had moderate aortic sclerosis, and seven (2%) had
severe aortic sclerosis. Coronary artery disease was docu-
mented in 315 (76%) of the patients, of whom 225 (54%)
presented with acute coronary syndromes, including MI in
74 (33%) and unstable angina in 151 (67%).
Aortic sclerosis and cardiovascular outcomes. By univar-
iate analysis, the presence of aortic sclerosis was associated
with age, hypertension, congestive heart failure, elevated
CRP, fibrinogen, and lower triglyceride levels (Table 1).
However, by multivariable analysis only age was associated
with the presence of aortic sclerosis (odds ratio  1.07, p 
0.0001). There were no differences in the incidence of acute
coronary syndromes on index admission between the groups
with normal and sclerotic aortic valves. However, a tendency
toward increased cardiovascular deaths during the index
admission was noted in patients with aortic sclerosis (p 
0.06) (Table 2).
Over one year, both the presence and severity of aortic
sclerosis were strongly associated with adverse cardiovascular
outcomes (Table 2). At one-year follow-up, those with aortic
valve involvement suffered an increased incidence of overall
mortality compared to those without aortic sclerosis (18.7% vs.
2.4%, p  0.0001) and cardiovascular mortality in particular
(14.7% vs. 1.4%, p  0.0001). The incidence of nonfatal MI
was no different between the two groups. The combined end
point of cardiovascular death or nonfatal MI at one year was
higher in patients with aortic sclerosis (16.7% vs. 7.1%, p 
Table 1. Univariate Association Between Baseline Clinical and Laboratory Variables and Aortic
Sclerosis
Variables
Normal
Aortic Valve
(n  212)
Any Aortic
Sclerosis
(n  203)
Mild Aortic
Sclerosis
(n  149)
Moderate-Severe
Aortic Sclerosis
(n  54)
Clinical variables
Age, yrs (mean  SD) 61.8  14.3 73.9  12* 73.5  12.7* 74.9  10.3*
Male gender 118 (56%) 105 (52%) 73 (49%) 32 (59%)
Caucasian race 176 (84%) 180 (89%) 133 (89%) 47 (90%)
History of hypertension 132 (63%) 151 (74%)† 112 (75%)† 39 (72%)
History of diabetes mellitus 51 (24%) 57 (28%) 38 (26%) 19 (35%)
History of hyperlipidemia 84 (40%) 85 (52%) 61 (41%) 24 (44%)
History of coronary heart disease‡ 101 (48%) 115 (57%) 84 (56%) 31 (57%)
History of congestive heart failure 22 (10%) 50 (25%)* 37 (25%)* 13 (24%)*
Smoking status
Current 35 (17%) 23 (12%) 20 (14%) 3 (6%)
Ever§ 117 (57%) 80 (40%) 75 (51%) 27 (50%)
Laboratory evaluation at baseline
C-reactive protein
Geometric mean (mg/dl) 0.55 0.78† 0.71 1.04†
Median (mg/dl) 0.48 0.8† 0.77† 1.05†
Fibrinogen
Geometric mean (mg/dl) 312 339† 334 351†
Median (mg/dl) 305 344† 344† 352†
Leukocyte count
Geometric mean (109/l) 7.8 7.9 8.1 7.6
Median (109/l) 7.9 7.6 7.8 7.25
Elevated troponin T ( 0.2 ng/ml) 31 (15%) 14 (7%) 31 (22%) 16 (30%)†
Total cholesterol (mg/dl, mean  SD) 180  43 173  38 175  38 168  35
LDL (mg/dl, mean  SD) 120  76 107  50† 108  48 104  54†
HDL (mg/dl, mean  SD) 44  13 46  15 47  15 43  14
Triglycerides (mg/dl, mean  SD) 175  180 133  93* 129  88† 147  107*
*p  0.001; †p  0.05 vs. normal aortic valve; ‡angiographic evidence of 50% lesion in at least one coronary artery or evidence
of myocardial ischemia on non-invasive testing; §10 pack-year smoking anytime in the past.
LDL  low density lipoprotein cholesterol; HDL  high-density lipoprotein cholesterol.
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0.003). Furthermore, Kaplan-Meier analysis showed a strong
association between increasing severity of aortic sclerosis and
adverse cardiovascular events at one year (Fig. 1), with event-
free survival of 93% in patients without aortic sclerosis, 85% in
mild aortic sclerosis, and 77% in moderate to severe aortic
sclerosis (p 0.0002). Adverse cardiovascular events were also
associated with CAD, elevated troponin-T (0.2 ng/ml),
increasing tertiles of CRP, fibrinogen and leukocyte counts,
age, hypertension, diabetes mellitus, and congestive heart
failure (Table 3).
CAD, inflammatory markers, and cardiovascular out-
comes. There was an incremental increase in adverse car-
diovascular events with both increasing magnitude of ele-
vation of inflammatory markers as well as severity of aortic
sclerosis (Fig. 2). In patients with moderate to severe aortic
sclerosis and the highest tertile CRP (1.18 mg/dl), there
was a striking fivefold increase in adverse events at one year
compared with the lowest tertile (0.32 mg/dl). The
event-free survival in patients with aortic sclerosis varied
inversely with increasing tertiles of CRP (Fig. 3).
Figure 4 depicts the cumulative incidence of cardiac death
and nonfatal MI either at index admission or at one-year
follow-up in patients with and without aortic sclerosis on
echocardiographic evaluation, with respect to their history
of documented CAD and the status of their systemic
inflammation at the time of admission. In 98 patients
without documented CAD (24%), we found a higher
incidence of cumulative events in the aortic sclerosis group
(9% vs. 0%, p  0.04), all of which were in those who also
had elevated CRP.
However, despite these findings by univariate and biva-
riate analyses, aortic sclerosis was not found to be an
independent predictor of adverse cardiovascular outcome
(Fig. 5). On multivariable analysis, independent predictors
of adverse cardiovascular outcomes at one year were docu-
mented CAD, presentation with acute MI at the time of
index admission, increasing tertiles of CRP, congestive
heart failure, and age.
CPIgG titers were available in 408 patients, of whom 314
Table 3. Unadjusted Risk of Adverse Cardiovascular Events at
12 Months
Variables Relative Risk 95% CI
Age 1.05 (1.02, 1.07)
Hypertension 2.21 (1.04, 4.71)
Diabetes mellitus 2.16 (1.17, 4.01)
Coronary heart disease 4.12 (2.0, 8.47)
Congestive heart failure 2.97 (1.55, 5.72)
Elevated troponin T (0.2 ng/ml) 2.68 (1.40, 5.14)
CRP (each tertile increase)* 1.52 (1.22, 1.88)
Fibrinogen (each tertile increase)† 1.88 (1.26, 2.80)
Lekocyte count (each tertile increase)‡ 1.7 (1.15, 2.50)
Aortic sclerosis
None 1
Mild 2.28 (1.14, 4.55)
Mod-severe 3.75 (1.64, 8.59)
Any 3.11 (1.71, 5.67)
*C-reactive protein tertiles: 0.32; 0.32–1.18; 1.18 (mg/dl); ‡leukocyte count
tertiles: 6.8; 6.8–9.0; 9.0 (109/l); and †fibrinogen tertiles: 282; 282–359.40;
359.40 (mg/dl).
CI  confidence interval; CRP  C-reactive protein.
Table 2. Aortic Sclerosis and Cardiovascular Outcomes
Variables
Normal
Aortic Valve
(n  212)
Any Aortic
Sclerosis
(n  203)
Mild
Sclerosis
(n  149)
Moderate-Severe
Sclerosis
(n  54)
Outcome at index admission
Acute coronary syndrome 121 (57%) 104 (51%) 74 (50%) 30 (56%)
Myocardial infarction 39 (18%) 35 (17%) 25 (17%) 10 (19%)
Unstable angina 82 (39%) 69 (34%) 49 (33%) 20 (37%)
In-hospital death 1 (0.5%) 7 (3%) 6 (4.0%)† 1 (1.9%)
Cardiovascular 1 (0.5%) 7 (3%) 6 (4.0%)† 1 (1.9%)
Noncardiovascular 0 0 0 0
Outcome at 12 months
Nonfatal myocardial infarction 12 (5.7%) 7 (3.4%) 2 (1.3%) 5 (9.3%)
Death 5 (2.4%) 38 (18.7%)* 27 (18.1%)* 11 (20.4%)*
Cardiovascular 3 (1.4%) 30 (14.7%)* 21 (14.1%)* 9 (16.7%)*
Noncardiovascular 2 (0.9%) 8 (3.9%) 6 (4.9%) 2 (4.0%)
Combined end point‡
(Cardiovascular death  MI) 15 (7.1%) 34 (16.7%)† 22 (14.8%)† 12 (22.2%)†
*p  0.001; †p  0.05 vs. normal aortic valve; ‡p for trend 0.005.
MI  myocardial infarction.
Figure 1. Kaplan-Meier analysis of event-free survival in patients accord-
ing to the severity of aortic sclerosis. Event-free survival  freedom from
cardiac death and nonfatal myocardial infarction.
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(77%) were positive at the lowest titer (1:64) and 122
(30%) were positive at or above the highest titer (1:1,024).
However, CPIgG titers were associated neither with aortic
sclerosis nor with outcomes either at index admission or at
one year. Furthermore, there was no association between the
CPIgG titers and the levels of inflammatory markers.
DISCUSSION
Observations from the present study suggest that the
increased incidence of adverse cardiovascular outcomes in
patients with aortic sclerosis is attributable to the effects of
CAD and inflammation, not a result of the effects of
valvular heart disease per se.
The present findings are consistent with and extend those
of prior studies documenting that patients with aortic
sclerosis are at increased risk of adverse cardiovascular events
(1–3). In this study, as in prior reports, patients with aortic
sclerosis suffered an increased incidence of adverse cardio-
vascular events. However, the present results demonstrate
that aortic sclerosis is not the mediator of adverse outcomes
but rather a marker of the presence of CAD and inflam-
mation, which together appear to be predominantly associ-
ated with the increased incidence of cardiovascular events.
Our data demonstrate that patients with acute coronary
syndromes, the greatest elevation of systemic inflammatory
markers, and more severe aortic sclerosis suffered the high-
est incidence of adverse cardiovascular events. Multivariable
analysis demonstrated that aortic sclerosis was not indepen-
dently associated with adverse cardiovascular events. The
strong relationship between aortic sclerosis and adverse
cardiovascular events noted on univariate analysis was ex-
plained by the presence of CAD and concomitant elevation
of inflammatory markers. Given the absence of a direct
association between aortic sclerosis and adverse outcomes by
Figure 3. Kaplan-Meier analysis of event-free survival in patients with
aortic sclerosis with respect to C-reactive protein (CRP) levels. Event-free
survival  freedom from cardiac death and nonfatal myocardial infarction.
Tertiles:0.32; 0.32 to 1.18;1.18 (mg/dl); levels available on 190 of 203
patients with aortic sclerosis.
Figure 4. Cumulative incidence of cardiac death and nonfatal myocardial
infarction either at index admission or at one year in patients with and
without known coronary artery disease (CAD) in relation to their aortic
valves (normal or any sclerosis by echocardiography) and systemic inflam-
mation (low C-reactive protein [CRP]  1st tertile, 0.32 vs. high CRP
 2nd and 3rd tertiles, 0.32 mg/dl); levels available on 395 of 415
patients; A.Scl  aortic sclerosis,   present,   absent.
Figure 5. Cox multivariate analysis: one-year outcome of cardiac death and
nonfatal myocardial infarction (MI). C.I.  confidence interval; CRP 
C-reactive protein. Tertiles 0.32; 0.32 to 1.18; 1.18 (mg/dl).
Figure 2. Incidence of cardiac death and nonfatal myocardial infarction
(MI) at one year by severity of aortic (A.) sclerosis and C-reactive protein
(CRP) tertiles. Tertiles: 0.32; 0.32 to 1.18; 1.18 (mg/dl); levels
available on 395 of 415 patients.
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multivariable analysis and the lack of a plausible indepen-
dent pathophysiologic link between nonobstructive aortic
sclerosis and cardiovascular events, the present data suggest
that aortic sclerosis is merely an indicator for the presence of
CAD and systemic inflammation, which constitute the
factors associated with adverse coronary events.
In the present study, in patients with aortic sclerosis the
presence and magnitude of elevated CRP was an indepen-
dent predictor of adverse cardiovascular events, a link likely
predominantly attributable to the direct pathophysiologic
association between CAD and active inflammation. Local
coronary inflammation is thought to play a fundamental
pathophysiologic role in the induction and progression of
chronic CAD (7–9). Acute plaque inflammation has been
implicated as a key factor precipitating plaque instability
resulting in acute coronary syndromes (8,9,11–15,24). Fur-
thermore, observations from angiographic and pathologic
studies support the concept that acute coronary artery
instability is a multifocal coronary process, likely reflecting
factors such as inflammation that adversely influence a
diffusely atherosclerotic coronary vasculature (16,17).
Whether elevation of systemic markers of inflammation in
patients with acute coronary syndromes reflects primary
local activation of inflammation in the coronary tree or
systemic activation of the immune system that secondarily
precipitates plaque instability is a subject of ongoing debate.
Regardless, such serologic markers are prognosticators of
short and long-term adverse cardiovascular events (18–22).
Furthermore, recent data suggest that CRP may also play a
complex modulatory function in the development and
evolution of inflammation/atherosclerosis by directly induc-
ing expression of adhesion molecules in human endothelial
cells (25).
The present findings documenting elevated inflammatory
markers and their association with adverse outcomes in
patients with aortic sclerosis are novel and provide the basis
for speculation regarding the mechanisms by which inflam-
mation imparts increased risk in such patients. It is likely
that the association between aortic sclerosis, cardiovascular
events, and inflammatory markers reflects a shared patho-
physiologic bond whereby inflammation plays a key role in
the pathogenesis of both aortic sclerosis and atherosclerosis.
Histopathologic studies in patients with aortic sclerosis
document the presence of lipid particles and inflammatory
infiltrates, including macrophages, T-lymphocytes, and ma-
trix metalloproteinase, features that are strikingly similar to
those seen in atherosclerosis (4–6). Risk factors implicated
as stimuli for inflammation, including smoking, elevated
low density lipoprotein cholesterol levels, hypertension, and
obesity, are common to both CAD and degenerative aortic
valve disease (1–3,26). Furthermore, endothelial injury at
sites of hemodynamic stress has been postulated as the key
factor inducing both coronary atherosclerosis and aortic
sclerosis (8,11,15,24). The present study demonstrates as-
sociations, not cause and effect, but together with these
observations the study provides the basis for speculation that
the inflammatory process that initiates, promotes, and
destabilizes coronary atherosclerosis also impacts the aortic
valve and contributes to the development of aortic sclerosis.
Thus, aortic sclerosis appears to be both a result of and a
marker for the adverse effects of inflammation in the
cardiovascular system. It is beyond the scope of the present
study to determine whether the local coronary and aortic
valve inflammation that appears to be common to the
pathophysiology of coronary atherosclerosis and aortic scle-
rosis reflects a single pathogenetic stimulus inducing injury
and inflammation in both vessel and valve or whether
inflammation (and its reflection in serologic markers) is a
coincidental response to independent unrelated injuries
from hyperlipidemia, smoking, hypertension, diabetes, or
infection.
There are important considerations pertinent to the
methods of this study. The emergency room chest pain
population may represent a group at higher risk for cardio-
vascular events. Echocardiographic evaluation was per-
formed in 51% of cases, which may constitute a selection
bias. Qualitative grading of aortic sclerosis is novel and
needs to be replicated in further studies. The present study
lacks angiographic and histopathologic data. On multivari-
able analysis the hazard ratio of 1.37 for aortic sclerosis
showed a tendency toward statistical significance (p 
0.139). It is possible that a larger sample size would have
shown aortic sclerosis to be an independent predictor of
adverse cardiovascular events.
The present study has potential prognostic and therapeu-
tic implications. On the basis of the present observations,
patients with aortic sclerosis may need to be considered for
testing to exclude CAD and analyze inflammatory markers.
Anti-inflammatory agents such as aspirin, known to exert
salutary effects on cardiovascular events in patients with
CAD (27), and statins, which reduce cardiovascular events
and lower the magnitude of systemic inflammation (28),
could be beneficial in patients with aortic sclerosis and
elevated inflammatory markers. Prospective studies will be
necessary to determine whether such diagnostic and thera-
peutic strategies can improve outcomes in these patients.
The severity of inflammation, which influences lesion pro-
gression and the clinical course in patients with unstable
coronary plaques (11,12,14,18,19,21) may also determine
the rate at which aortic sclerosis progresses. The present
study found a linear association between inflammatory
markers and severity of aortic sclerosis. Prospective longi-
tudinal studies correlating levels of inflammatory markers
with rates of aortic sclerosis progression will be necessary to
determine whether the severity and duration of systemic
inflammation influence which sclerotic valves will progress
to become clinically stenotic.
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